Global Metastatic Melanoma Diagnostic Market Insights, Forecast to 2029
This report presents an overview of global market for Metastatic Melanoma Diagnostic market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Metastatic Melanoma Diagnostic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Metastatic Melanoma Diagnostic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Metastatic Melanoma Diagnostic revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Metastatic Melanoma Diagnostic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Metastatic Melanoma Diagnostic revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Metastatic Melanoma Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metastatic Melanoma Diagnostic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metastatic Melanoma Diagnostic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Metastatic Melanoma Diagnostic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Metastatic Melanoma Diagnostic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Metastatic Melanoma Diagnostic revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Metastatic Melanoma Diagnostic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Metastatic Melanoma Diagnostic revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc.
By Company
- Myriad Genetics
- Abbott Laboratories
- Foundation Medicine
- Pathway Genomics Corporation
- Cancer Genetics
- Castle Biosciences
- NeoGenomics
- Dermtech
- Sysmex Inostics
- BRAF Mutation
- Circulating Tumor Cells (CTCs)
- Immunohistochemistry
- Others
- Pathology Laboratories
- Hospitals
- Cancer Research Centres
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Metastatic Melanoma Diagnostic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metastatic Melanoma Diagnostic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metastatic Melanoma Diagnostic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 BRAF Mutation
1.2.3 Circulating Tumor Cells (CTCs)
1.2.4 Immunohistochemistry
1.2.5 Others
1.3 Market by Application
1.3.1 Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pathology Laboratories
1.3.3 Hospitals
1.3.4 Cancer Research Centres
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Metastatic Melanoma Diagnostic Market Perspective (2018-2029)
2.2 Global Metastatic Melanoma Diagnostic Growth Trends by Region
2.2.1 Metastatic Melanoma Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Metastatic Melanoma Diagnostic Historic Market Size by Region (2018-2023)
2.2.3 Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Metastatic Melanoma Diagnostic Market Dynamics
2.3.1 Metastatic Melanoma Diagnostic Industry Trends
2.3.2 Metastatic Melanoma Diagnostic Market Drivers
2.3.3 Metastatic Melanoma Diagnostic Market Challenges
2.3.4 Metastatic Melanoma Diagnostic Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Metastatic Melanoma Diagnostic by Players
3.1.1 Global Metastatic Melanoma Diagnostic Revenue by Players (2018-2023)
3.1.2 Global Metastatic Melanoma Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Metastatic Melanoma Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Metastatic Melanoma Diagnostic, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Metastatic Melanoma Diagnostic Market Concentration Ratio
3.4.1 Global Metastatic Melanoma Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Melanoma Diagnostic Revenue in 2022
3.5 Global Key Players of Metastatic Melanoma Diagnostic Head office and Area Served
3.6 Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
3.7 Global Key Players of Metastatic Melanoma Diagnostic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY TYPE
4.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029)
5 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY APPLICATION
5.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Metastatic Melanoma Diagnostic Market Size (2018-2029)
6.2 North America Metastatic Melanoma Diagnostic Market Size by Type
6.2.1 North America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
6.2.2 North America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
6.2.3 North America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
6.3 North America Metastatic Melanoma Diagnostic Market Size by Application
6.3.1 North America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
6.3.2 North America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
6.3.3 North America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
6.4 North America Metastatic Melanoma Diagnostic Market Size by Country
6.4.1 North America Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
6.4.3 North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Metastatic Melanoma Diagnostic Market Size (2018-2029)
7.2 Europe Metastatic Melanoma Diagnostic Market Size by Type
7.2.1 Europe Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
7.2.2 Europe Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
7.2.3 Europe Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
7.3 Europe Metastatic Melanoma Diagnostic Market Size by Application
7.3.1 Europe Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
7.3.2 Europe Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
7.3.3 Europe Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
7.4 Europe Metastatic Melanoma Diagnostic Market Size by Country
7.4.1 Europe Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
7.4.3 Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Metastatic Melanoma Diagnostic Market Size (2018-2029)
8.2 China Metastatic Melanoma Diagnostic Market Size by Type
8.2.1 China Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
8.2.2 China Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
8.2.3 China Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
8.3 China Metastatic Melanoma Diagnostic Market Size by Application
8.3.1 China Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
8.3.2 China Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
8.3.3 China Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Metastatic Melanoma Diagnostic Market Size (2018-2029)
9.2 Asia Metastatic Melanoma Diagnostic Market Size by Type
9.2.1 Asia Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
9.2.2 Asia Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
9.2.3 Asia Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
9.3 Asia Metastatic Melanoma Diagnostic Market Size by Application
9.3.1 Asia Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
9.3.2 Asia Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
9.3.3 Asia Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
9.4 Asia Metastatic Melanoma Diagnostic Market Size by Region
9.4.1 Asia Metastatic Melanoma Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Metastatic Melanoma Diagnostic Market Size by Region (2018-2023)
9.4.3 Asia Metastatic Melanoma Diagnostic Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Myriad Genetics
11.1.1 Myriad Genetics Company Details
11.1.2 Myriad Genetics Business Overview
11.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Introduction
11.1.4 Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.1.5 Myriad Genetics Recent Developments
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Introduction
11.2.4 Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.2.5 Abbott Laboratories Recent Developments
11.3 Foundation Medicine
11.3.1 Foundation Medicine Company Details
11.3.2 Foundation Medicine Business Overview
11.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Introduction
11.3.4 Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.3.5 Foundation Medicine Recent Developments
11.4 Pathway Genomics Corporation
11.4.1 Pathway Genomics Corporation Company Details
11.4.2 Pathway Genomics Corporation Business Overview
11.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Introduction
11.4.4 Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.4.5 Pathway Genomics Corporation Recent Developments
11.5 Cancer Genetics
11.5.1 Cancer Genetics Company Details
11.5.2 Cancer Genetics Business Overview
11.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Introduction
11.5.4 Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.5.5 Cancer Genetics Recent Developments
11.6 Castle Biosciences
11.6.1 Castle Biosciences Company Details
11.6.2 Castle Biosciences Business Overview
11.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Introduction
11.6.4 Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.6.5 Castle Biosciences Recent Developments
11.7 NeoGenomics
11.7.1 NeoGenomics Company Details
11.7.2 NeoGenomics Business Overview
11.7.3 NeoGenomics Metastatic Melanoma Diagnostic Introduction
11.7.4 NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.7.5 NeoGenomics Recent Developments
11.8 Dermtech
11.8.1 Dermtech Company Details
11.8.2 Dermtech Business Overview
11.8.3 Dermtech Metastatic Melanoma Diagnostic Introduction
11.8.4 Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.8.5 Dermtech Recent Developments
11.9 Sysmex Inostics
11.9.1 Sysmex Inostics Company Details
11.9.2 Sysmex Inostics Business Overview
11.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Introduction
11.9.4 Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.9.5 Sysmex Inostics Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 BRAF Mutation
1.2.3 Circulating Tumor Cells (CTCs)
1.2.4 Immunohistochemistry
1.2.5 Others
1.3 Market by Application
1.3.1 Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pathology Laboratories
1.3.3 Hospitals
1.3.4 Cancer Research Centres
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Metastatic Melanoma Diagnostic Market Perspective (2018-2029)
2.2 Global Metastatic Melanoma Diagnostic Growth Trends by Region
2.2.1 Metastatic Melanoma Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Metastatic Melanoma Diagnostic Historic Market Size by Region (2018-2023)
2.2.3 Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029)
2.3 Metastatic Melanoma Diagnostic Market Dynamics
2.3.1 Metastatic Melanoma Diagnostic Industry Trends
2.3.2 Metastatic Melanoma Diagnostic Market Drivers
2.3.3 Metastatic Melanoma Diagnostic Market Challenges
2.3.4 Metastatic Melanoma Diagnostic Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Metastatic Melanoma Diagnostic by Players
3.1.1 Global Metastatic Melanoma Diagnostic Revenue by Players (2018-2023)
3.1.2 Global Metastatic Melanoma Diagnostic Revenue Market Share by Players (2018-2023)
3.2 Global Metastatic Melanoma Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Metastatic Melanoma Diagnostic, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Metastatic Melanoma Diagnostic Market Concentration Ratio
3.4.1 Global Metastatic Melanoma Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Melanoma Diagnostic Revenue in 2022
3.5 Global Key Players of Metastatic Melanoma Diagnostic Head office and Area Served
3.6 Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
3.7 Global Key Players of Metastatic Melanoma Diagnostic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY TYPE
4.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Type (2018-2023)
4.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029)
5 METASTATIC MELANOMA DIAGNOSTIC BREAKDOWN DATA BY APPLICATION
5.1 Global Metastatic Melanoma Diagnostic Historic Market Size by Application (2018-2023)
5.2 Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Metastatic Melanoma Diagnostic Market Size (2018-2029)
6.2 North America Metastatic Melanoma Diagnostic Market Size by Type
6.2.1 North America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
6.2.2 North America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
6.2.3 North America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
6.3 North America Metastatic Melanoma Diagnostic Market Size by Application
6.3.1 North America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
6.3.2 North America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
6.3.3 North America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
6.4 North America Metastatic Melanoma Diagnostic Market Size by Country
6.4.1 North America Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
6.4.3 North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Metastatic Melanoma Diagnostic Market Size (2018-2029)
7.2 Europe Metastatic Melanoma Diagnostic Market Size by Type
7.2.1 Europe Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
7.2.2 Europe Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
7.2.3 Europe Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
7.3 Europe Metastatic Melanoma Diagnostic Market Size by Application
7.3.1 Europe Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
7.3.2 Europe Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
7.3.3 Europe Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
7.4 Europe Metastatic Melanoma Diagnostic Market Size by Country
7.4.1 Europe Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
7.4.3 Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Metastatic Melanoma Diagnostic Market Size (2018-2029)
8.2 China Metastatic Melanoma Diagnostic Market Size by Type
8.2.1 China Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
8.2.2 China Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
8.2.3 China Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
8.3 China Metastatic Melanoma Diagnostic Market Size by Application
8.3.1 China Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
8.3.2 China Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
8.3.3 China Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Metastatic Melanoma Diagnostic Market Size (2018-2029)
9.2 Asia Metastatic Melanoma Diagnostic Market Size by Type
9.2.1 Asia Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
9.2.2 Asia Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
9.2.3 Asia Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
9.3 Asia Metastatic Melanoma Diagnostic Market Size by Application
9.3.1 Asia Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
9.3.2 Asia Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
9.3.3 Asia Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
9.4 Asia Metastatic Melanoma Diagnostic Market Size by Region
9.4.1 Asia Metastatic Melanoma Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Metastatic Melanoma Diagnostic Market Size by Region (2018-2023)
9.4.3 Asia Metastatic Melanoma Diagnostic Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Myriad Genetics
11.1.1 Myriad Genetics Company Details
11.1.2 Myriad Genetics Business Overview
11.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Introduction
11.1.4 Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.1.5 Myriad Genetics Recent Developments
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Details
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Introduction
11.2.4 Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.2.5 Abbott Laboratories Recent Developments
11.3 Foundation Medicine
11.3.1 Foundation Medicine Company Details
11.3.2 Foundation Medicine Business Overview
11.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Introduction
11.3.4 Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.3.5 Foundation Medicine Recent Developments
11.4 Pathway Genomics Corporation
11.4.1 Pathway Genomics Corporation Company Details
11.4.2 Pathway Genomics Corporation Business Overview
11.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Introduction
11.4.4 Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.4.5 Pathway Genomics Corporation Recent Developments
11.5 Cancer Genetics
11.5.1 Cancer Genetics Company Details
11.5.2 Cancer Genetics Business Overview
11.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Introduction
11.5.4 Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.5.5 Cancer Genetics Recent Developments
11.6 Castle Biosciences
11.6.1 Castle Biosciences Company Details
11.6.2 Castle Biosciences Business Overview
11.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Introduction
11.6.4 Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.6.5 Castle Biosciences Recent Developments
11.7 NeoGenomics
11.7.1 NeoGenomics Company Details
11.7.2 NeoGenomics Business Overview
11.7.3 NeoGenomics Metastatic Melanoma Diagnostic Introduction
11.7.4 NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.7.5 NeoGenomics Recent Developments
11.8 Dermtech
11.8.1 Dermtech Company Details
11.8.2 Dermtech Business Overview
11.8.3 Dermtech Metastatic Melanoma Diagnostic Introduction
11.8.4 Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.8.5 Dermtech Recent Developments
11.9 Sysmex Inostics
11.9.1 Sysmex Inostics Company Details
11.9.2 Sysmex Inostics Business Overview
11.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Introduction
11.9.4 Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023)
11.9.5 Sysmex Inostics Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of BRAF Mutation
Table 3. Key Players of Circulating Tumor Cells (CTCs)
Table 4. Key Players of Immunohistochemistry
Table 5. Key Players of Others
Table 6. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Metastatic Melanoma Diagnostic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Metastatic Melanoma Diagnostic Market Share by Region (2018-2023)
Table 10. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Metastatic Melanoma Diagnostic Market Share by Region (2024-2029)
Table 12. Metastatic Melanoma Diagnostic Market Trends
Table 13. Metastatic Melanoma Diagnostic Market Drivers
Table 14. Metastatic Melanoma Diagnostic Market Challenges
Table 15. Metastatic Melanoma Diagnostic Market Restraints
Table 16. Global Metastatic Melanoma Diagnostic Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Metastatic Melanoma Diagnostic Revenue Share by Players (2018-2023)
Table 18. Global Top Metastatic Melanoma Diagnostic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Table 19. Global Metastatic Melanoma Diagnostic Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Metastatic Melanoma Diagnostic Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Metastatic Melanoma Diagnostic, Headquarters and Area Served
Table 22. Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
Table 23. Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2018-2023)
Table 27. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2024-2029)
Table 29. Global Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Metastatic Melanoma Diagnostic Revenue Share by Application (2018-2023)
Table 31. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Metastatic Melanoma Diagnostic Revenue Share by Application (2024-2029)
Table 33. North America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Metastatic Melanoma Diagnostic Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 65. Myriad Genetics Company Details
Table 66. Myriad Genetics Business Overview
Table 67. Myriad Genetics Metastatic Melanoma Diagnostic Product
Table 68. Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 69. Myriad Genetics Recent Developments
Table 70. Abbott Laboratories Company Details
Table 71. Abbott Laboratories Business Overview
Table 72. Abbott Laboratories Metastatic Melanoma Diagnostic Product
Table 73. Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 74. Abbott Laboratories Recent Developments
Table 75. Foundation Medicine Company Details
Table 76. Foundation Medicine Business Overview
Table 77. Foundation Medicine Metastatic Melanoma Diagnostic Product
Table 78. Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 79. Foundation Medicine Recent Developments
Table 80. Pathway Genomics Corporation Company Details
Table 81. Pathway Genomics Corporation Business Overview
Table 82. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product
Table 83. Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 84. Pathway Genomics Corporation Recent Developments
Table 85. Cancer Genetics Company Details
Table 86. Cancer Genetics Business Overview
Table 87. Cancer Genetics Metastatic Melanoma Diagnostic Product
Table 88. Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 89. Cancer Genetics Recent Developments
Table 90. Castle Biosciences Company Details
Table 91. Castle Biosciences Business Overview
Table 92. Castle Biosciences Metastatic Melanoma Diagnostic Product
Table 93. Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 94. Castle Biosciences Recent Developments
Table 95. NeoGenomics Company Details
Table 96. NeoGenomics Business Overview
Table 97. NeoGenomics Metastatic Melanoma Diagnostic Product
Table 98. NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 99. NeoGenomics Recent Developments
Table 100. Dermtech Company Details
Table 101. Dermtech Business Overview
Table 102. Dermtech Metastatic Melanoma Diagnostic Product
Table 103. Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 104. Dermtech Recent Developments
Table 105. Sysmex Inostics Company Details
Table 106. Sysmex Inostics Business Overview
Table 107. Sysmex Inostics Metastatic Melanoma Diagnostic Product
Table 108. Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 109. Sysmex Inostics Recent Developments
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 1. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of BRAF Mutation
Table 3. Key Players of Circulating Tumor Cells (CTCs)
Table 4. Key Players of Immunohistochemistry
Table 5. Key Players of Others
Table 6. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Metastatic Melanoma Diagnostic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Metastatic Melanoma Diagnostic Market Share by Region (2018-2023)
Table 10. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Metastatic Melanoma Diagnostic Market Share by Region (2024-2029)
Table 12. Metastatic Melanoma Diagnostic Market Trends
Table 13. Metastatic Melanoma Diagnostic Market Drivers
Table 14. Metastatic Melanoma Diagnostic Market Challenges
Table 15. Metastatic Melanoma Diagnostic Market Restraints
Table 16. Global Metastatic Melanoma Diagnostic Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Metastatic Melanoma Diagnostic Revenue Share by Players (2018-2023)
Table 18. Global Top Metastatic Melanoma Diagnostic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Table 19. Global Metastatic Melanoma Diagnostic Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Metastatic Melanoma Diagnostic Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Metastatic Melanoma Diagnostic, Headquarters and Area Served
Table 22. Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
Table 23. Global Key Players of Metastatic Melanoma Diagnostic, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2018-2023)
Table 27. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type (2024-2029)
Table 29. Global Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Metastatic Melanoma Diagnostic Revenue Share by Application (2018-2023)
Table 31. Global Metastatic Melanoma Diagnostic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Metastatic Melanoma Diagnostic Revenue Share by Application (2024-2029)
Table 33. North America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Metastatic Melanoma Diagnostic Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Metastatic Melanoma Diagnostic Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size by Country (2024-2029) & (US$ Million)
Table 65. Myriad Genetics Company Details
Table 66. Myriad Genetics Business Overview
Table 67. Myriad Genetics Metastatic Melanoma Diagnostic Product
Table 68. Myriad Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 69. Myriad Genetics Recent Developments
Table 70. Abbott Laboratories Company Details
Table 71. Abbott Laboratories Business Overview
Table 72. Abbott Laboratories Metastatic Melanoma Diagnostic Product
Table 73. Abbott Laboratories Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 74. Abbott Laboratories Recent Developments
Table 75. Foundation Medicine Company Details
Table 76. Foundation Medicine Business Overview
Table 77. Foundation Medicine Metastatic Melanoma Diagnostic Product
Table 78. Foundation Medicine Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 79. Foundation Medicine Recent Developments
Table 80. Pathway Genomics Corporation Company Details
Table 81. Pathway Genomics Corporation Business Overview
Table 82. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product
Table 83. Pathway Genomics Corporation Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 84. Pathway Genomics Corporation Recent Developments
Table 85. Cancer Genetics Company Details
Table 86. Cancer Genetics Business Overview
Table 87. Cancer Genetics Metastatic Melanoma Diagnostic Product
Table 88. Cancer Genetics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 89. Cancer Genetics Recent Developments
Table 90. Castle Biosciences Company Details
Table 91. Castle Biosciences Business Overview
Table 92. Castle Biosciences Metastatic Melanoma Diagnostic Product
Table 93. Castle Biosciences Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 94. Castle Biosciences Recent Developments
Table 95. NeoGenomics Company Details
Table 96. NeoGenomics Business Overview
Table 97. NeoGenomics Metastatic Melanoma Diagnostic Product
Table 98. NeoGenomics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 99. NeoGenomics Recent Developments
Table 100. Dermtech Company Details
Table 101. Dermtech Business Overview
Table 102. Dermtech Metastatic Melanoma Diagnostic Product
Table 103. Dermtech Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 104. Dermtech Recent Developments
Table 105. Sysmex Inostics Company Details
Table 106. Sysmex Inostics Business Overview
Table 107. Sysmex Inostics Metastatic Melanoma Diagnostic Product
Table 108. Sysmex Inostics Revenue in Metastatic Melanoma Diagnostic Business (2018-2023) & (US$ Million)
Table 109. Sysmex Inostics Recent Developments
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Metastatic Melanoma Diagnostic Market Share by Type: 2022 VS 2029
Figure 3. BRAF Mutation Features
Figure 4. Circulating Tumor Cells (CTCs) Features
Figure 5. Immunohistochemistry Features
Figure 6. Others Features
Figure 7. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Metastatic Melanoma Diagnostic Market Share by Application: 2022 VS 2029
Figure 9. Pathology Laboratories Case Studies
Figure 10. Hospitals Case Studies
Figure 11. Cancer Research Centres Case Studies
Figure 12. Others Case Studies
Figure 13. Metastatic Melanoma Diagnostic Report Years Considered
Figure 14. Global Metastatic Melanoma Diagnostic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Metastatic Melanoma Diagnostic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Metastatic Melanoma Diagnostic Market Share by Region: 2022 VS 2029
Figure 17. Global Metastatic Melanoma Diagnostic Market Share by Players in 2022
Figure 18. Global Top Metastatic Melanoma Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Metastatic Melanoma Diagnostic Revenue in 2022
Figure 20. North America Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 22. North America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 23. North America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 24. United States Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 28. Europe Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 29. Europe Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 30. Germany Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 38. China Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 39. Asia Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 41. Asia Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 42. Asia Metastatic Melanoma Diagnostic Market Share by Region (2018-2029)
Figure 43. Japan Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 53. Brazil Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Myriad Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 60. Abbott Laboratories Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 61. Foundation Medicine Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 62. Pathway Genomics Corporation Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 63. Cancer Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 64. Castle Biosciences Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 65. NeoGenomics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 66. Dermtech Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 67. Sysmex Inostics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Figure 1. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Metastatic Melanoma Diagnostic Market Share by Type: 2022 VS 2029
Figure 3. BRAF Mutation Features
Figure 4. Circulating Tumor Cells (CTCs) Features
Figure 5. Immunohistochemistry Features
Figure 6. Others Features
Figure 7. Global Metastatic Melanoma Diagnostic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Metastatic Melanoma Diagnostic Market Share by Application: 2022 VS 2029
Figure 9. Pathology Laboratories Case Studies
Figure 10. Hospitals Case Studies
Figure 11. Cancer Research Centres Case Studies
Figure 12. Others Case Studies
Figure 13. Metastatic Melanoma Diagnostic Report Years Considered
Figure 14. Global Metastatic Melanoma Diagnostic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Metastatic Melanoma Diagnostic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Metastatic Melanoma Diagnostic Market Share by Region: 2022 VS 2029
Figure 17. Global Metastatic Melanoma Diagnostic Market Share by Players in 2022
Figure 18. Global Top Metastatic Melanoma Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Diagnostic as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Metastatic Melanoma Diagnostic Revenue in 2022
Figure 20. North America Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 22. North America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 23. North America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 24. United States Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 28. Europe Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 29. Europe Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 30. Germany Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 38. China Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 39. Asia Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 41. Asia Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 42. Asia Metastatic Melanoma Diagnostic Market Share by Region (2018-2029)
Figure 43. Japan Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Metastatic Melanoma Diagnostic Market Share by Country (2018-2029)
Figure 53. Brazil Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Metastatic Melanoma Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Myriad Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 60. Abbott Laboratories Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 61. Foundation Medicine Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 62. Pathway Genomics Corporation Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 63. Cancer Genetics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 64. Castle Biosciences Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 65. NeoGenomics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 66. Dermtech Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 67. Sysmex Inostics Revenue Growth Rate in Metastatic Melanoma Diagnostic Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
